D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
NextCure, Inc. (NASDAQ:NXTC) reported Monday that its shareholders approved all proposals at the company’s 2025 Annual Meeting of Stockholders held Friday.
According to a statement based on a SEC filing, shareholders elected three Class III directors—David Kabakoff, Ph.D., Michael Richman, and Stephen W. Webster—to serve three-year terms expiring at the 2028 annual meeting. The directors will remain in office until their successors are elected or until earlier death, resignation, or removal.
Shareholders also ratified the appointment of Ernst & Young LLP as NextCure’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 18,767,121 votes in favor, 1,434,513 against, and 502 abstentions.
On an advisory basis, shareholders approved the compensation paid to the company’s named executive officers, with 11,316,309 votes for, 421,792 against, and 14,006 abstentions. In a separate advisory vote, shareholders agreed to hold the executive compensation vote annually, with 11,664,330 votes for a one-year frequency, 2,631 for two years, 43,161 for three years, and 41,985 abstentions.
In addition, shareholders approved an amendment to NextCure’s Amended and Restated Certificate of Incorporation to authorize a reverse stock split at a ratio and time to be determined by the board of directors. The reverse split proposal received 18,166,577 votes in favor, 2,028,946 against, and 6,613 abstentions.
A sixth proposal regarding adjournment of the annual meeting was not presented, as it became moot following approval of the reverse split proposal.
The information in this article is based on a press release statement and the company’s filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.